Theophylline: Old Drug in a New Light, Application in COVID-19 through Computational Studies
Luis Montaño, Bettina Sommer, Juan Carlos Gómez-Verján, Genaro Salvador Morales-Paoli, G. Lizbeth Ramírez-Salinas, Héctor Solís‐Chagoyán, Zuly A. Sánchez-Florentino, Eduardo Calixto, Gloria Figueroa, Rohan Carter, Ruth Jaimez, Bianca S. Romero-Martínez, Edgar Flores‐Soto
Abstract
Theophylline (3-methyxanthine) is a historically prominent drug used to treat respiratory diseases, alone or in combination with other drugs. The rapid onset of the COVID-19 pandemic urged the development of effective pharmacological treatments to directly attack the development of new variants of the SARS-CoV-2 virus and possess a therapeutical battery of compounds that could improve the current management of the disease worldwide. In this context, theophylline, through bronchodilatory, immunomodulatory, and potentially antiviral mechanisms, is an interesting proposal as an adjuvant in the treatment of COVID-19 patients. Nevertheless, it is essential to understand how this compound could behave against such a disease, not only at a pharmacodynamic but also at a pharmacokinetic level. In this sense, the quickest approach in drug discovery is through different computational methods, either from network pharmacology or from quantitative systems pharmacology approaches. In the present review, we explore the possibility of using theophylline in the treatment of COVID-19 patients since it seems to be a relevant candidate by aiming at several immunological targets involved in the pathophysiology of the disease. Theophylline down-regulates the inflammatory processes activated by SARS-CoV-2 through various mechanisms, and herein, they are discussed by reviewing computational simulation studies and their different applications and effects.